News › Industry News, Patient Care

WHO Identifies Falsified Batch Numbers in Medical Product Alert N°2/2024: Falsified Ozempic (semaglutide)

July 12, 2024
Injection pens

The World Health Organization (WHO) released a Medical Product Alert describing three falsified batches of Ozempic that were detected in Brazil, the U.K. and the U.S. in 2023. Ozempic’s manufacturer, Novo Nordisk, confirmed for the WHO that the products detected has misrepresented their identity and source, and where not manufactured by Novo Nordisk. The false identifiers are as follows:

  • Batch number LP6F832 is not recognized.
  • The combination of batch number NAR0074 with serial number 430834149057 does not correspond to genuine manufacturing records.
  • Batch number MP5E511 is genuine, but the product is falsified.

Health care professionals are encouraged to report adverse effects, lack of effectiveness and suspected falsification to the National Regulatory Authorities/National Pharmacovigilance Centre.

Read the full alert at World Health Organization >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics